Lexaria Bioscience (LEXX) Other Operating Expenses (2017 - 2022)

Lexaria Bioscience has disclosed Other Operating Expenses across 6 years of filings, most recently posting $1.5 million for Q3 2022.

• Other Operating Expenses for Q3 2022 came in at $1.5 million, changed N/A year-over-year; the trailing twelve-month figure through May 2023 was $1.5 million (changed N/A YoY), and the FY2022 annual result was $1.5 million, changed 0.0% from the prior year.
• Other Operating Expenses came in at $1.5 million for Q3 2022 at Lexaria Bioscience, roughly flat from $1.5 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $1.5 million in Q1 2021 to a low of -$247835.0 in Q4 2020.
• The 5-year median for Other Operating Expenses is $769583.0 (2019), against an average of $686245.9.
• Across the five-year window, Other Operating Expenses jumped 25846.55% in 2019 and tumbled 132.2% in 2020, its largest moves.
• Lexaria Bioscience's Other Operating Expenses stood at $627731.0 in 2018, then rose by 22.6% to $769583.0 in 2019, then sank by 132.2% to -$247835.0 in 2020, then surged by 714.4% to $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022.
• The last three Other Operating Expenses figures came in at $1.5 million (Q3 2022), $1.5 million (Q1 2021), and -$247835.0 (Q4 2020), per Business Quant data.